Beijing – October 13, 2026 -- Likang Life Sciences, whose lead cancer vaccine candidate LK101 holds clinical trial authorization from China's NMPA (2023) and U.S. FDA IND clearance (2025), will sponsor and exhibit at the Abu Dhabi Future Health Summit 2026 on October 20–22 at the ADNEC Centre.